Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 1312

1.

Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue.

Yun SJ, Jeong P, Kang HW, Shinn HK, Kim YH, Yan C, Choi YK, Kim D, Ryu DH, Ha YS, Kim TH, Kwon TG, Kim JM, Suh SH, Kim SK, Kim SY, Kim ST, Kim WT, Lee OJ, Moon SK, Kim NH, Kim IY, Kim J, Cha HJ, Choi YH, Cha EJ, Kim WJ.

Int Neurourol J. 2016 Jun;20(2):122-30. doi: 10.5213/inj.1632552.276. Epub 2016 Jun 24.

2.

Occurrence of double primary malignancies in an African renal transplant recipient.

Mohan P, Yuvaraj A, Abraham G, Kurien A, Abraham A, Mathew M, Saravanan S, Nair S.

Saudi J Kidney Dis Transpl. 2016 Mar;27(2):377-80. doi: 10.4103/1319-2442.178566.

3.

CD24 Is Not Required for Tumor Initiation and Growth in Murine Breast and Prostate Cancer Models.

Cremers N, Neeb A, Uhle T, Dimmler A, Rothley M, Allgayer H, Fodde R, Sleeman JP, Thiele W.

PLoS One. 2016 Mar 15;11(3):e0151468. doi: 10.1371/journal.pone.0151468. eCollection 2016.

4.

Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.

Graff RE, Pettersson A, Lis RT, Ahearn TU, Markt SC, Wilson KM, Rider JR, Fiorentino M, Finn S, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Mucci LA.

Am J Clin Nutr. 2016 Mar;103(3):851-60. doi: 10.3945/ajcn.115.118703. Epub 2016 Jan 27.

PMID:
26817504
5.

Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.

Shen YH, Yang F, Wang H, Cai ZJ, Xu YP, Zhao A, Su Y, Zhang G, Zhu SX.

PLoS One. 2016 Jan 22;11(1):e0147173. doi: 10.1371/journal.pone.0147173. eCollection 2016.

6.

Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.

Hwang JE, Joung JY, Shin SP, Choi MK, Kim JE, Kim YH, Park WS, Lee SJ, Lee KH.

Cancer Lett. 2016 Mar 1;372(1):57-64. doi: 10.1016/j.canlet.2015.12.018. Epub 2015 Dec 23.

7.

Functional screen identifies kinases driving prostate cancer visceral and bone metastasis.

Faltermeier CM, Drake JM, Clark PM, Smith BA, Zong Y, Volpe C, Mathis C, Morrissey C, Castor B, Huang J, Witte ON.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E172-81. doi: 10.1073/pnas.1521674112. Epub 2015 Nov 30.

8.

Virus encoded circulatory miRNAs for early detection of prostate cancer.

Kim J, Yun SJ, Kim WJ.

BMC Urol. 2015 Nov 26;15:116. doi: 10.1186/s12894-015-0111-9. Review.

9.

Frequency of PTEN alterations, TMPRSS2-ERG fusion and their association in prostate cancer.

Fallahabadi ZR, Noori Daloii MR, Mahdian R, Behjati F, Shokrgozar MA, Abolhasani M, Asgari M, Shahrokh H.

Gene. 2016 Jan 10;575(2 Pt 3):755-60. doi: 10.1016/j.gene.2015.09.068. Epub 2015 Sep 28.

PMID:
26424596
10.

[Construction of a lentiviral vector of FoxM1 shRNA and its transfection into human prostate cancer cell lines in vitro].

Wang Y, Yao B, Zhang Y, Zhang M, Gao H, Tang J.

Nan Fang Yi Ke Da Xue Xue Bao. 2015 Aug;35(9):1227-33. Chinese.

PMID:
26403729
11.

Polyomavirus Hominis 1(BK virus) Infection in Prostatic Tissues: Cancer versus Hyperplasia.

Taghavi A, Mohammadi-Torbati P, Kashi AH, Rezaee H, Vaezjalali M.

Urol J. 2015 Sep 4;12(4):2240-4.

12.

Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

Riabov V, Tretyakova I, Alexander RB, Pushko P, Klyushnenkova EN.

Vaccine. 2015 Oct 5;33(41):5386-95. doi: 10.1016/j.vaccine.2015.08.062. Epub 2015 Aug 28.

PMID:
26319744
13.

Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre.

Ong WL, Manohar P, Millar J, Royce P.

BJU Int. 2015 Oct;116 Suppl 3:5-10. doi: 10.1111/bju.13097. Epub 2015 Aug 28.

PMID:
26315395
14.

Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.

Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.

Cancer. 2015 Nov 15;121(22):4071-9. doi: 10.1002/cncr.29611. Epub 2015 Aug 17.

PMID:
26280815
15.

The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.

Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.

Am J Pathol. 2015 Oct;185(10):2722-30. doi: 10.1016/j.ajpath.2015.06.013. Epub 2015 Aug 10.

PMID:
26272362
16.

Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.

Pandya M, Britt K, Hoffman B, Ling C, Aslanidi GV.

J Immunother. 2015 Sep;38(7):292-8. doi: 10.1097/CJI.0000000000000093.

PMID:
26261893
17.

Development of PROSTVAC immunotherapy in prostate cancer.

Singh P, Pal SK, Alex A, Agarwal N.

Future Oncol. 2015;11(15):2137-48. doi: 10.2217/fon.15.120.

18.

Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?

Carozzi F, Tamburrino L, Bisanzi S, Marchiani S, Paglierani M, Di Lollo S, Crocetti E, Buzzoni C, Burroni E, Greco L, Baldi E, Sani C.

J Cancer Res Clin Oncol. 2016 Jan;142(1):201-12. doi: 10.1007/s00432-015-2015-1. Epub 2015 Jul 26.

PMID:
26210155
19.

High Frequency of JCV DNA Detection in Prostate Cancer Tissues.

Anzivino E, Rodio DM, Mischitelli M, Bellizzi A, Sciarra A, Salciccia S, Gentile V, Pietropaolo V.

Cancer Genomics Proteomics. 2015 Jul-Aug;12(4):189-200.

PMID:
26136219
20.

Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.

Mao LJ, Zhang J, Liu N, Fan L, Yang DR, Xue BX, Shan YX, Zheng JN.

Tumour Biol. 2015 Nov;36(11):9073-81. doi: 10.1007/s13277-015-3658-x. Epub 2015 Jun 19.

PMID:
26084613
Items per page

Supplemental Content

Loading ...
Write to the Help Desk